Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 3/20 | 0.33 |
| ▸ | RXRB | P28702 | 3/20 | 0.33 |
| ▸ | RXRG | P48443 | 3/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 2/20 | 0.32 |
| ▸ | THRA | P10827 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 2/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13554240 | 0.84 | RXRA (0.35) | RXRARXRBRXRGS1PR1MGLL | |
| SCHEMBL13554248 | 0.80 | ENPP2 (0.31) | ENPP2 | |
| SCHEMBL29955864 | 0.78 | RXRA (0.50) | RXRARXRBRXRGS1PR1MGLL | |
| SCHEMBL3113375 | 0.78 | RXRA (0.50) | RXRARXRBRXRGS1PR1MGLL | |
| SCHEMBL13554242 | 0.77 | ENPP2 (0.39) | ENPP2 | |
| SCHEMBL10290933 | 0.76 | KDM4E (0.41) | RXRARXRBRXRGS1PR1MGLL | |
| SCHEMBL3587911 | 0.75 | AAK1 (0.38) | RXRARXRBRXRGS1PR1MGLL | |
| SCHEMBL13665316 | 0.75 | S1PR1 (0.55) | S1PR1MGLLTHRATHRB | |
| SCHEMBL1629456 | 0.74 | S1PR1 (0.44) | S1PR1MGLLCTSSCTSK | |
| SCHEMBL13554243 | 0.73 | MGLL (0.36) | RXRARXRBRXRGMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | RXRA 2610/4885RXRB 2718/4885RXRG 3287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.